Hèctor López-Laguna, Eloi Parladé, Marianna T. P. Favaro, Carlos Palacín, Eric Voltà-Durán, Neus Ferrer-Miralles, José Luis Corchero, Rosalía Rodríguez-Rodríguez, Esther Vázquez, Ugutz Unzueta, Antonio Villaverde
Springer Nature ·
2026-05-13
· DOI 10.1007/s40259-026-00783-z
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Hèctor López-Laguna, Eloi Parladé, Marianna T. P. Favaro, Carlos Palacín, Eric Voltà-Durán, Neus Ferrer-Miralles et al. Recombinant Protein Drugs: A 2025 Update. // BioDrugs. – 2026. – DOI: 10.1007/s40259-026-00783-z. – URL: https://doi.org/10.1007/s40259-026-00783-z
Hèctor López-Laguna, Eloi Parladé, Marianna T. P. Favaro, Carlos Palacín, Eric Voltà-Durán, Neus Ferrer-Miralles, José Luis Corchero, Rosalía Rodríguez-Rodríguez, Esther Vázquez, Ugutz Unzueta, & Antonio Villaverde (2026). Recombinant Protein Drugs: A 2025 Update. BioDrugs. https://doi.org/10.1007/s40259-026-00783-z
Hèctor López-Laguna, et al. “Recombinant Protein Drugs: A 2025 Update.” BioDrugs, 2026. doi:10.1007/s40259-026-00783-z.
@article{LpezLaguna2026,
title = {Recombinant Protein Drugs: A 2025 Update},
author = {López-Laguna, Hèctor and Parladé, Eloi and Favaro, Marianna T. P. and Palacín, Carlos and Voltà-Durán, Eric and Ferrer-Miralles, Neus and Corchero, José Luis and Rodríguez-Rodríguez, Rosalía and Vázquez, Esther and Unzueta, Ugutz and Villaverde, Antonio},
journal = {BioDrugs},
year = {2026},
doi = {10.1007/s40259-026-00783-z},
url = {https://doi.org/10.1007/s40259-026-00783-z}
}